Sarepta Therapeutics, Inc.
SRPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $6 | $12 |
| - Cash | $1 | $1 | $0 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $3 | $3 | $7 | $12 |
| Revenue | $0 | $1 | $1 | $1 |
| % Growth | -34.6% | -18% | 13.1% | – |
| Gross Profit | $0 | $0 | $1 | $1 |
| % Margin | 62.2% | 75% | 81.5% | 79.9% |
| EBITDA | -$0 | $0 | -$0 | $0 |
| % Margin | -42.1% | 27.8% | -49.5% | 28.4% |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -45.1% | 32.2% | -60.1% | 24.2% |
| EPS Diluted | -1.795 | 1.89 | -4.6 | 1.5 |
| % Growth | -195% | 141.1% | -406.7% | – |
| Operating Cash Flow | $0 | $0 | -$1 | $0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$1 | $0 |